BioDelivery Sciences International

News & Media

These are news releases that are related to our Investor efforts.  Releases are listed in chronological order and are archived by year.  Sign-up to receive news as it is released via email or RSS.

Archives: Search / 2012 / 2011

May 10, 2012
BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its First Quarter 2012 Financials
Signed licensing agreement with Endo Pharmaceuticals for BEMA Buprenorphine for chronic pain worth up to $180 million plus royalties
May 9, 2012
BioDelivery Sciences to Present at the Bank of America Merrill Lynch 2012 Healthcare Conference
Apr 17, 2012
BioDelivery Sciences Awarded Patent Resulting in $15 Million Milestone Payment
Patent extends exclusivity protection for BEMA Buprenorphine and BEMA Buprenorphine/Naloxone (BNX) through 2027
Apr 16, 2012
BioDelivery Sciences to Present at the Future Leaders in the Biotech Industry Conference
Apr 5, 2012
BioDelivery Sciences to Host Opioid Dependence Investor Event and Webcast on April 11, 2012
Event will focus on the treatment of Opioid Dependence and the BNX development program
 
 
Media inquiries

Contact Al Medwar

at 919-582-9050

amedwar@bdsi.com